(Q51624577)

8 April 2018

title

Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. (English)

1 reference

8 April 2018

1 reference

1

1 reference

8 April 2018

author name string

R A Noel

2

1 reference

8 April 2018

B S Levitan

3

1 reference

8 April 2018

J Ferguson

4

1 reference

8 April 2018

F Mussen

5

1 reference

8 April 2018

language of work or name

English

0 references

publication date

15 December 2010

1 reference

8 April 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

8 April 2018

volume

89

1 reference

8 April 2018

issue

2

1 reference

8 April 2018

page(s)

312-315

1 reference

8 April 2018

A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

Protecting the health of the public--Institute of Medicine recommendations on drug safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

Safe drugs and the cost of good intentions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

7 January 2021

Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

7 January 2021

Benefit-risk analysis: a proposal using quantitative methods

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

7 January 2021

A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

7 January 2021

Palliative care and the QALY problem

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.291

7 January 2021

Identifiers

DOI

10.1038/CLPT.2010.291

1 reference

8 April 2018

1 reference

8 April 2018